Biohit Oyj (BIOBV.HE)
EUR 2.52
(0.1%)
EUR 2.52
(0.1%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.3 Million EUR | -95.08% |
| 2022 | -1.17 Million EUR | -33.83% |
| 2021 | -881 Thousand EUR | -34.09% |
| 2020 | -657 Thousand EUR | 36.71% |
| 2019 | -1.03 Million EUR | 21.12% |
| 2018 | -1.31 Million EUR | -4.2% |
| 2017 | -1.26 Million EUR | -111.56% |
| 2016 | -597 Thousand EUR | -0.34% |
| 2015 | -595 Thousand EUR | -69.03% |
| 2014 | -352 Thousand EUR | -324.1% |
| 2013 | -83 Thousand EUR | -161.03% |
| 2012 | 136 Thousand EUR | 100.32% |
| 2011 | -43 Million EUR | -650.97% |
| 2010 | 7.8 Million EUR | 5.6% |
| 2009 | 7.39 Million EUR | -4.99% |
| 2008 | 7.78 Million EUR | -2.96% |
| 2007 | 8.01 Million EUR | 17.04% |
| 2006 | 6.85 Million EUR | 6.76% |
| 2005 | 6.41 Million EUR | 127.68% |
| 2004 | 2.81 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -1.4 Million EUR | 21.43% |
| 2024 Q1 | -1.4 Million EUR | 39.13% |
| 2023 Q3 | -2.6 Million EUR | -188.89% |
| 2023 FY | -2.3 Million EUR | -95.08% |
| 2023 Q2 | -900 Thousand EUR | 25.0% |
| 2023 Q4 | -2.3 Million EUR | 11.54% |
| 2023 Q1 | -1.2 Million EUR | -1.78% |
| 2022 Q4 | -1.17 Million EUR | 17.9% |
| 2022 FY | -1.17 Million EUR | -33.83% |
| 2022 Q3 | -1.43 Million EUR | -187.2% |
| 2022 Q2 | -500 Thousand EUR | 37.5% |
| 2022 Q1 | -800 Thousand EUR | 9.19% |
| 2021 Q3 | -940 Thousand EUR | -56.67% |
| 2021 Q2 | -600 Thousand EUR | 25.0% |
| 2021 Q1 | -800 Thousand EUR | -21.77% |
| 2021 FY | -881 Thousand EUR | -34.09% |
| 2021 Q4 | -881 Thousand EUR | 6.28% |
| 2020 Q1 | -900 Thousand EUR | 13.29% |
| 2020 Q2 | -700 Thousand EUR | 22.22% |
| 2020 Q3 | -907 Thousand EUR | -29.57% |
| 2020 Q4 | -657 Thousand EUR | 27.56% |
| 2020 FY | -657 Thousand EUR | 36.71% |
| 2019 Q2 | -1 Million EUR | 16.67% |
| 2019 FY | -1.03 Million EUR | 21.12% |
| 2019 Q1 | -1.2 Million EUR | 8.81% |
| 2019 Q4 | -1.03 Million EUR | 18.01% |
| 2019 Q3 | -1.26 Million EUR | -26.6% |
| 2018 Q2 | -1.2 Million EUR | 0.0% |
| 2018 Q3 | -1.33 Million EUR | -11.08% |
| 2018 FY | -1.31 Million EUR | -4.2% |
| 2018 Q1 | -1.2 Million EUR | 4.99% |
| 2018 Q4 | -1.31 Million EUR | 1.28% |
| 2017 Q3 | -1.28 Million EUR | -220.0% |
| 2017 FY | -1.26 Million EUR | -111.56% |
| 2017 Q2 | -400 Thousand EUR | 0.0% |
| 2017 Q4 | -1.26 Million EUR | 1.33% |
| 2017 Q1 | -400 Thousand EUR | 33.0% |
| 2016 Q4 | -597 Thousand EUR | 0.0% |
| 2016 Q1 | -500 Thousand EUR | 15.97% |
| 2016 Q2 | -400 Thousand EUR | 20.0% |
| 2016 Q3 | -597 Thousand EUR | -49.25% |
| 2016 FY | -597 Thousand EUR | -0.34% |
| 2015 Q2 | -600 Thousand EUR | 0.0% |
| 2015 Q1 | -600 Thousand EUR | -70.45% |
| 2015 FY | -595 Thousand EUR | -69.03% |
| 2015 Q4 | -595 Thousand EUR | 0.83% |
| 2015 Q3 | -600 Thousand EUR | 0.0% |
| 2014 Q3 | -200 Thousand EUR | 33.33% |
| 2014 FY | -352 Thousand EUR | -324.1% |
| 2014 Q4 | -352 Thousand EUR | -76.0% |
| 2014 Q2 | -300 Thousand EUR | 95.77% |
| 2014 Q1 | -7.1 Million EUR | -8454.22% |
| 2013 Q1 | -2.6 Million EUR | -2011.76% |
| 2013 Q3 | -100 Thousand EUR | -200.0% |
| 2013 Q4 | -83 Thousand EUR | 17.0% |
| 2013 Q2 | 100 Thousand EUR | 103.85% |
| 2013 FY | -83 Thousand EUR | -161.03% |
| 2012 Q4 | 136 Thousand EUR | 36.0% |
| 2012 Q2 | -1.6 Million EUR | -45.45% |
| 2012 FY | 136 Thousand EUR | 100.32% |
| 2012 Q3 | 100 Thousand EUR | 106.25% |
| 2012 Q1 | -1.1 Million EUR | 97.44% |
| 2011 Q1 | 7.7 Million EUR | -1.36% |
| 2011 Q3 | 9 Million EUR | -8.16% |
| 2011 Q2 | 9.8 Million EUR | 27.27% |
| 2011 Q4 | -43 Million EUR | -577.88% |
| 2011 FY | -43 Million EUR | -650.97% |
| 2010 Q1 | 7.9 Million EUR | 6.87% |
| 2010 Q2 | 7.5 Million EUR | -5.06% |
| 2010 FY | 7.8 Million EUR | 5.6% |
| 2010 Q3 | 7.8 Million EUR | 4.0% |
| 2010 Q4 | 7.8 Million EUR | 0.08% |
| 2009 Q4 | 7.39 Million EUR | 0.0% |
| 2009 FY | 7.39 Million EUR | -4.99% |
| 2008 FY | 7.78 Million EUR | -2.96% |
| 2007 FY | 8.01 Million EUR | 17.04% |
| 2006 FY | 6.85 Million EUR | 6.76% |
| 2005 FY | 6.41 Million EUR | 127.68% |
| 2004 FY | 2.81 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Herantis Pharma Oyj | -5.46 Million EUR | 57.939% |
| Nanoform Finland Oyj | -7.97 Million EUR | 71.157% |